Scarica l'app Stockscreener
41.93
1.22%
-0.52
Dopo l'orario di chiusura:
42.01
0.08
+0.19%
Precedente Chiudi:
$42.45
Aprire:
$42.29
Volume 24 ore:
1.27M
Relative Volume:
1.41
Capitalizzazione di mercato:
$3.38B
Reddito:
-
Utile/perdita netta:
$-64.16M
Rapporto P/E:
-33.01
EPS:
-1.2702
Flusso di cassa netto:
$-69.06M
1 W Prestazione:
+0.99%
1M Prestazione:
-2.03%
6M Prestazione:
+61.52%
1 anno Prestazione:
+37.66%
Intervallo 1D:
$41.00
$42.98
Intervallo di 1 settimana:
$39.14
$43.43
Portata 52W:
$14.80
$46.01
Cg Oncology Inc Stock (CGON) Company Profile
Nome
Cg Oncology Inc
Settore
Industria
Telefono
(949) 419-6203
Indirizzo
400 SPECTRUM CENTER DRIVE, IRVINE
Confronta CGON con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
41.93 | 3.42B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-11 | Iniziato | Wedbush | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-08 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-05-02 | Iniziato | JP Morgan | Overweight |
| 2025-04-16 | Iniziato | Scotiabank | Sector Perform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2024-06-28 | Iniziato | BofA Securities | Buy |
| 2024-02-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Iniziato | Goldman | Neutral |
| 2024-02-20 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-14 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cg Oncology Inc Borsa (CGON) Ultime notizie
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Will CG Oncology Inc. stock split again soonQuarterly Portfolio Report & Weekly Breakout Watchlists - ulpravda.ru
Can CG Oncology Inc. stock maintain growth trajectoryJuly 2025 Highlights & Low Risk Profit Maximizing Plans - ulpravda.ru
Why analysts upgrade CG Oncology Inc. stockTake Profit Strategies & Free Robust Financial Gains - ulpravda.ru
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
CG Oncology Announces Participation in 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
CG Oncology (NASDAQ:CGON) Shares Down 6.3%Here's What Happened - MarketBeat
Midday Stock Roundup: Skyworks Solutions down 12% - Orange County Business Journal
Big Picture: Is CG Oncology Inc stock trading at a premium valuationEarnings Beat & Community Trade Idea Sharing Platform - moha.gov.vn
CG Oncology Earnings Notes - Trefis
Voya Investment Management LLC Has $1.93 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Piper Sandler initiates coverage of oncology companies - MSN
12 Health Care Stocks Moving In Monday's After-Market Session - Sahm
enGene Holdings: A Potential Oncology Entrant (NASDAQ:ENGN) - Seeking Alpha
CG Oncology Appoints Christina Rossi to Board - MSN
CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON) - Seeking Alpha
CG Oncology, Inc. (CGON): Investor Outlook Reveals 76% Potential Upside In Biotech Stock - DirectorsTalk Interviews
CG Oncology (CGON): Differentiated NMIBC Profile and Broad Market Strategy Support Upside and Buy Rating - TipRanks
SUO-CTC CG Oncology NMIBC Research Fellowship - Oncodaily
Will CG Oncology Inc. stock continue upward momentum2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC DataWhat's Changed - Sahm
Why CG Oncology Inc. stock is in analyst buy zoneMarket Rally & Real-Time Volume Trigger Notifications - DonanımHaber
Is CG Oncology Inc. stock supported by strong cash flows2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
Will CG Oncology Inc. stock beat EPS estimatesJuly 2025 Rallies & Risk Controlled Daily Plans - Улправда
Aug Summary: Why analysts upgrade CG Oncology Inc. stockChart Signals & Weekly High Return Opportunities - Улправда
Is CG Oncology Inc. stock a safe investment in uncertain marketsGold Moves & Low Risk Growth Stock Ideas - Улправда
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
SUO-CTC and CG Oncology Announce the Second Annual - GlobeNewswire
CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CG Oncology Inc Stock Analysis and ForecastHigh Yield Income Stocks & Technical + Fundamental = Smarter Investing - earlytimes.in
CG Oncology appoints Rossi to its Board of Directors - MSN
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 26,000 CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ:CGON) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
CG Oncology initiated with an Outperform at Wedbush - TipRanks
Wedbush initiates coverage on CG Oncology stock with Outperform rating By Investing.com - Investing.com Canada
How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story - Yahoo Finance
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities - Insider Monkey
CG Oncology (CGON) Valuation Check After Strong Late-Breaking Cretostimogene Bladder Cancer Trial Results - Sahm
Promising Prospects for CG Oncology, Inc.: Buy Rating Backed by Cretostimogene’s Potential in NMIBC Market - TipRanks
CG Oncology (NASDAQ:CGON) Sets New 1-Year HighStill a Buy? - MarketBeat
Cg Oncology Inc. (CGON) Live Share Price, Invest From India - INDmoney
CG Oncology, Inc. (CGON) stock price, news, quote and history - Yahoo Finance UK
CG Oncology Incannounced topline data from Bond-003 cohort P and first results from Core-008 cohort A - marketscreener.com
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times
CG Oncology Reports Promising Efficacy and Safety Data for Cretostimogene in High-Risk Non-Muscle Invasive Bladder Cancer Trials - Quiver Quantitative
CG Oncology (NASDAQ: CGON) posts 83.7% CR, no Grade 3+ AEs in NMIBC trial data - Stock Titan
Schroder Investment Management Group Acquires 155,737 Shares of CG Oncology, Inc. $CGON - MarketBeat
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC - Urology Times
Will CG Oncology’s (CGON) Board Refresh and Cretostimogene Data Shape Its Bladder Cancer Strategy? - Sahm
Muscle Invasive Bladder Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, LLC, Protara Therapeutics, Binhui Biopharma - The Globe and Mail
Cg Oncology Inc Azioni (CGON) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):